Diffusion Pharmaceuticals Inc. announced that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies was featured in a poster presentation at the Alzheimer's Association International Conference. They also announced that Company management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference.